YALA vs. NVO
YALA (Yalla Group Limited) and NVO (Novo Nordisk A/S) are both stocks. YALA operates in Software - Application (Technology), while NVO operates in Drug Manufacturers - General (Healthcare). Over the past 5 years, YALA returned -20.23%/yr vs 4.91%/yr for NVO. At a 0.12 correlation, their price movements are largely independent.
Performance
YALA vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, YALA achieves a -22.48% return, which is significantly lower than NVO's 0.65% return.
YALA
- 1D
- -0.37%
- 1M
- -0.19%
- 6M
- -23.69%
- YTD
- -22.48%
- 1Y
- -27.40%
- 3Y*
- 3.16%
- 5Y*
- -20.23%
- 10Y*
- —
NVO
- 1D
- 1.23%
- 1M
- 12.56%
- 6M
- -12.92%
- YTD
- 0.65%
- 1Y
- -24.87%
- 3Y*
- -11.12%
- 5Y*
- 4.91%
- 10Y*
- 8.17%
YALA vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
YALA Yalla Group Limited | -22.48% | 70.94% | -33.77% | 75.14% | -47.84% | -53.18% | 46.97% |
NVO Novo Nordisk A/S | 0.65% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | -0.53% |
Correlation
The correlation between YALA and NVO is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.18 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.12 |
Correlation (All Time) Calculated using the full available price history since Sep 30, 2020 | 0.12 |
Fundamentals
YALA:
$830.70M
NVO:
$219.88B
YALA:
$0.80
NVO:
DKK 27.42
YALA:
6.77
NVO:
11.78
YALA:
0.43
NVO:
0.51
YALA:
2.84
NVO:
4.38
YALA:
1.14
NVO:
7.08
YALA:
$337.07M
NVO:
DKK 327.80B
YALA:
$227.87M
NVO:
DKK 268.30B
YALA:
$124.32M
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
YALA vs. NVO — Risk / Return Rank
YALA
NVO
YALA vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Yalla Group Limited (YALA) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| YALA | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.24 | ||
| Sortino ratioReturn per unit of downside risk | -0.56 | ||
| Omega ratioGain probability vs. loss probability | 0.88 | 0.94 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | -0.64 | -0.55 | -0.08 |
| Martin ratioReturn relative to average drawdown | -1.14 | -0.86 | -0.28 |
Loading charts...
Drawdowns
YALA vs. NVO - Drawdown Comparison
The maximum YALA drawdown since its inception was -92.42%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for YALA and NVO.
Loading charts...
Drawdown Indicators
| YALA | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.42% | -74.70% | -17.72% |
Max Drawdown (1Y)Largest decline over 1 year | -44.16% | -49.17% | +5.01% |
Max Drawdown (3Y)Largest decline over 3 years | -44.16% | -74.70% | +30.54% |
Max Drawdown (5Y)Largest decline over 5 years | -81.71% | -74.70% | -7.01% |
Max Drawdown (10Y)Largest decline over 10 years | — | -74.70% | — |
Current DrawdownCurrent decline from peak | -86.76% | -64.05% | -22.71% |
Average DrawdownAverage peak-to-trough decline | -78.76% | -17.86% | -60.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.57% | 31.50% | -6.93% |
Volatility
YALA vs. NVO - Volatility Comparison
Yalla Group Limited (YALA) has a higher volatility of 11.59% compared to Novo Nordisk A/S (NVO) at 8.69%. This indicates that YALA's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| YALA | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.59% | 8.69% | +2.90% |
Volatility (6M)Calculated over the trailing 6-month period | 24.52% | 37.47% | -12.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 36.58% | 51.76% | -15.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 54.23% | 38.52% | +15.71% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 70.07% | 32.59% | +37.48% |
Dividends
YALA vs. NVO - Dividend Comparison
YALA has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.64%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NVO Novo Nordisk A/S | 3.64% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
YALA Yalla Group Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
YALA vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Yalla Group Limited and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
YALA vs. NVO - Profitability Comparison
YALA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Yalla Group Limited reported a gross profit of 52.54M and revenue of 79.01M. Therefore, the gross margin over that period was 66.5%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
YALA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Yalla Group Limited reported an operating income of 23.46M and revenue of 79.01M, resulting in an operating margin of 29.7%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
YALA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Yalla Group Limited reported a net income of 28.94M and revenue of 79.01M, resulting in a net margin of 36.6%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
YALA and NVO have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
YALA has higher volatility (11.59%) compared to NVO (8.69%). In terms of maximum drawdown, YALA dropped -92.42% vs NVO's -74.70%.
NVO currently has the higher Sharpe Ratio (-0.53 vs -0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for YALA and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer